1

Serine recombinases are conserved genetic markers of antiphage defense systems

Shelby E. Andersen[1], Joshua M. Kirsch[1], Navtej Singh[1], Stephen R. Garret[3,4], John C. Whitney[3,4], Jay R.

Hesselberth[2], Breck A. Duerkop[1,#]

[1]Department of Immunology and Microbiology, University of Colorado School – Anschutz Medical

Campus, School of Medicine, Aurora, CO, USA, 80045

[2]Department of Biochemistry and Molecular Genetics, University of Colorado School – Anschutz Medical

Campus, School of Medicine, Aurora, CO, USA, 80045

[3]Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada,

L8S 4L8

[4]Michael DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON,

Canada L8S 4L8

[#]Correspondence: Breck A. Duerkop, breck.duerkop@cuanschutz.edu

<u>Abstract</u>

Antiphage defense systems confer bacteriophage (phage) resistance in bacteria. Renewed interest in

phage therapy indicates a need to understand the breadth and molecular mechanisms of antiphage

defenses. Traditionally, strategies to identify antiphage defenses lack throughput or are biased toward

model bacterial. Herein, we developed a bioinformatic pipeline that uses a serine recombinase to identify

known and unknown antiphage defense systems. Using this approach to query reference genomes and

metagenomes, we show that serine recombinase genes are genetically linked to antiphage defense

systems and serve as bait for finding these systems across diverse bacterial phyla. Using co-transcription

predictions and statistical analysis of protein domain abundances, we experimentally validated our

informatic approach by discovering that KAP P-loop NTPases are fused to putative antiphage effector

domains. Our work shows that serine recombinases are a reliable genetic marker for the discovery of

antiphage defenses across bacterial phyla.

Introduction

Multi-drug resistant (MDR) bacterial infections are a serious public health threat. With limited treatment options available for these infections, bacteriophage (phage) therapy has re-emerged as a potential treatment option[1-3]. Antiphage defense systems adapt to phages to overcome predation which threatens the efficacy of phage therapies[4]. Therefore, understanding the breadth, activity, and evolution of antiphage defenses in bacteria will inform the development of successful phage therapies.

Antiphage defense systems are routinely discovered by the tendency of these systems to localize in so-called 'defense islands', wherein uncharacterized phage defense systems are identified by their proximity to other known defense systems, or by generating genomic libraires and screening these in a heterologous bacterial host for phage defense[5-9]. To date, a marker gene that is broadly associated with various antiphage defenses across diverse bacteria has not been identified. Additionally, our knowledge of antiphage defense systems stems mostly from model bacteria such as *Escherichia coli* and *Bacillus subtilis*[5,8,10-13]. Well-studied antiphage defenses, such as abortive infection, restriction modification, and CRISPR/Cas, are widespread throughout bacterial phyla; however, the majority of the more recently discovered antiphage defense systems are poorly represented among diverse phyla and are biased to the Proteobacteria[14]. This indicates that utilizing defense islands or random cloning as the primary means of discovering novel systems likely excludes much of the diversity in antiphage defense biology and necessitates deeper studies across the bacterial domain of life.

Mobile genetic elements (MGEs), including plasmids, temperate phages, and transposons are significant drivers of genetic diversity in bacteria. MGEs are capable of spreading genetic traits that support bacterial fitness, such as antibiotic resistance genes and bacterial immunity genes to toxins[15,16]. Recent studies show that antiphage defense systems localize within the boundaries of MGEs[17-20]. For example, temperate phages and other phage-like elements are "hotspots" for antiphage defenses, and mobilizable antibiotic resistance cassettes can harbor and disseminate antiphage defenses[10,21]. Finally, genes that support DNA mobilization including recombinases, integrases, and transposon-encoding insertion sequence elements are often embedded within or near antiphage defense islands[19,22]. This

indicates that broadly conserved MGE-specific genes could be leveraged as bait to identify antiphage

defenses beyond those already discovered.

We recently characterized a Type IV restriction enzyme (TIV-RE, EF_B0059) from *Enterococcus*

faecalis that is encoded on a bicistronic mRNA with a serine recombinase (EF_B0058)[23]. The TIV-RE

restricts phage replication in *E. faecalis*, while the co-transcribed serine recombinase is dispensable for

phage resistance, suggesting that instead, the serine recombinase has evolved to perform an unknown

function associated with the genetic maintenance of this TIV-RE defense system. Thus, we hypothesized

that other antiphage defense systems could be found in the genomic regions surrounding homologs of

these serine recombinases and may also be co-transcribed. To explore this idea, we developed a

bioinformatic pipeline termed Recombinase Associated Defense Search (RADS) that searches for serine

recombinase homologs and captures their surrounding genomic context. Using the RADS pipeline to

query bacterial genomes and metagenomic contigs, we identified a plethora of antiphage defense

systems. RADS identifies antiphage defenses spanning diverse bacterial phyla. Using binomial statistical

testing coupled with co-transcription prediction to prioritize genes to further interrogate, we discover

previously uncharacterized antiphage defense systems. We show that KAP NTPase domains regulate

the function of linked effector modules that mediate antiphage defense. Because it relies on a conserved

serine recombinase rather than known antiphage defense genes, RADS is a uniquely unbiased method

for locating antiphage defense systems in diverse bacteria.

Materials & Methods

Plasmids

Plasmid constructs were generated by Genscript through synthesis of the nucleotide sequence

of interest and cloning each gene into the *Enterococcus* plasmid pLZ12A that harbors a constitutive

promoter[24]. Site directed mutagenesis of antiphage defense genes were generated where mutations of

interest were designed into the primers used for amplification. These primers were used for whole plasmid

PCR amplification using Q5 High-Fidelity 2X DNA polymerase Master Mix (New England Biolabs) to

create a linear DNA product. PCR products were purified using a QIAquick PCR Purification Kit (Qiagen) and linearized products were ligated using T4 DNA ligase (New England Biolabs). Ligated plasmids were transformed into electrocompetent *E. coli* TG1 DUOs (Lucigen). Plasmids were purified from *E. coli* using a Plasmid Mini Prep Kit (Qiagen) and transformed into electrocompetent *E. faecalis* using the lysozyme treatment method[24]. Plasmids and primers used can be found in Supplemental Table 1.

Bacteria and bacteriophages

A list of bacterial and bacteriophage strains used in this study can be found in Supplemental Table 1. *E. faecalis* strains were grown with aeration in Todd Hewitt broth (THB, Becton Dickinson) or on THB agar at 37°C. *Escherichia coli* was grown in Lennox lysogeny broth (LB, Fisher) with aeration or on LB agar at 37°C. When necessary, for the selection of *E. coli* or *E. faecalis* carrying a plasmid of interest, 15 µg/mL chloramphenicol (Research Products International) was added to the media. Phage plaque assays were performed using THB base and top agar supplemented with 10 mM $MgSO_4$ as described elsewhere[25].

Bacterial growth curves

Overnight cultures of *E. faecalis* were grown in THB broth with 15µg/mL chloramphenicol. Overnight cultures were diluted to an OD_{600} of 0.3 in THB broth with 15µg/mL chloramphenicol and 10mM $MgSO_4$. 200µL of the diluted culture was added to the appropriate wells of a 96-well plate. The appropriate volume of phage diluted in SM-plus buffer (100 mM NaCl, 50 mM Tris-HCl, 8 mM $MgSO_4$, 5 mM $CaCl_2$ [pH 7.4]) was added to the appropriate samples. Samples were set up in technical triplicate. The 96-well plate was then moved to 37°C with orbital shaking. Bacterial growth was measured by optical density (OD_{600}) every 5 minutes using a Biotek Synergy H1 Microplate reader.

Bioinformatics

Development of the Recombinase Associated Defense Search (RADS) pipeline. RADS first predicts ORFs in genomes or metagenomic contigs and translates them to amino acid sequences using prodigal[26]. Prodigal is used for de novo generation of ORFs within genomes and contigs rather than using the protein files from NCBI because the nascent ORF headers have the data in an easily queried format for downstream extraction. These amino acid sequences are then used to generate a BLASTp database using Diamond[27]. The Diamond BLASTp database is searched for homologs of the EF_B0058 serine recombinase with high (≥65%), or moderate (≥30%) amino acid identity. Once the genomic coordinates of serine recombinase homologs are identified, Seqkit is used to extract the 5kB flanking DNA sequence up- and downstream of the serine recombinase gene (designated as a RADS contig)[28]. RADS can be tuned to extract a region of a preferred size, but defaults to 5 kb on each side of the serine recombinase gene for a total of 10kb. These contigs are then run through InterProScan, returning a table of putative domains and predicted structural similarities for each ORF across the 10kb region queried[29]. RADS will also generate a list of predicted co-transcribed ORFs in which the downstream ORF must be on the same DNA strand and within 100 base pairs of the serine recombinase gene (**Fig. S2A**). RADS has been incorporated with functions so that each step of the pipeline may be independently called as long as the dependent files have been generated.

Analysis of RADS output data. Binomial statistical analysis for enrichment of domains in RADS contigs (**Fig. 1B, S2B**) is run in RStudio. The binomial analysis compares the frequency of a domain being found in a RADS contig to its frequency in the entirety of the genome to reveal domains that are truly enriched in RADS contigs (**Fig. S2B**). To run the binomial analysis, InterProScan must be run on all sequences where serine recombinase homologs were found. Known antiphage systems are confirmed using DefenseFinder[14]. Recombinase discovery rate was calculated by the number of recombinase homologs discovered divided by the number of input sequences. Antiphage discovery rate was calculated by the number of antiphage defense systems identified by DefenseFinder HMMer divided by the number of contigs discovered by RADS. All protein modeling was performed with Alphafold3[30].

Pipeline availability. RADS is available for download at https://github.com/Seandersen/RADS.

Computational recommendations. As with all bioinformatic approaches, RADS exhibits computational limits. While RADS was successfully run on 190,280 genomes from the Bacillota phylum for this study, the pipeline took considerable computation time and resources. This is due in part to translation of each coding sequence in a genome or contig, as well as the time it takes for InterProScan to run analyses on each ORF for domain prediction. While possible to run RADS on an entire phylum of bacterial nucleotide sequences from NCBI, the pipeline is more manageable with a smaller number of input files. This study was completed on a supercomputing system with 80CPU and allocating up to 62GB of RAM. The maximum cores allotted for this pipeline was 40CPU for the BLASTp step. The pipeline has been incorporated with a threads option where the number of CPU to be used can be specified.

Metagenomics analyses. Assembled metagenomes were downloaded from their respective data sources (Human Microbiome Project or Ma *et al*. 2023)[31,32]. Taxonomy classification was performed using Kraken2[33]. The human fecal microbiome metagenomes were taxonomically classified with the Phanta database, while the soil microbiome metagenome was taxonomically classified with the with the Plus_PF_16 database.

Results

Development of an informatic pipeline that identifies antiphage defense systems

The observation that a TIV-RE defense system (EF_B0059) in *Enterococcus faecalis* is encoded on a shared mRNA transcript with a predicted serine recombinase (EF_B0058, **Fig. 1A**)[23] led us to hypothesize that serine recombinases may co-occur in genomic regions with antiphage defense genes. To test this, we devised a bioinformatic approach that identifies serine recombinases homologous to the *E. faecalis* serine recombinase EF_B0058, extracts the surrounding DNA sequence, and predicts the

Figure 1. RADS leverages a serine recombinases associated with antiphage defense. (A) Graphic depicting the locus that inspired RADS. EF_B0058 is a serine recombinase that is co-transcribed with EF_B0059, a TIV restriction enzyme on the large conjugative plasmid pTEF2. (B) Graphic depicting the RADS bioinformatic pipeline.

surrounding open reading frames (ORFs) that are then assessed for antiphage defense genes (**Fig. 1B**).

We call this bioinformatic strategy Recombinase Associated Defense Search (RADS).

E. faecalis belongs to the Bacillota phylum. Therefore, to test whether RADS could identify

previously discovered antiphage defense genes, we ran the pipeline on all genomes belonging to the

Bacillota from NCBI (accessed August 2022). RADS identified 904 high homology (≥65% amino acid

identity) EF_B0058-like serine recombinases in 95,140 genomes, resulting in a discovery rate of 0.95%.

We next sought to provide evidence that the homologs of EF_B0058 identified by RADS were likely to

be proteins with demonstrated serine recombinase activity. Therefore, we took the nine lowest homology

matches to EF_B0058 and ran Alphafold3 modelling on these homologs and EF_B0058[30]. These

predicted structures were then aligned to the predicted structure of the *Escherichia* phage Mu serine

recombinase – a previously characterized serine recombinase (**Fig. 2A**)[34]. The predicted structures of

these proteins are nearly identical with an average RMSD value of 1.4Å between them, suggesting that

these are true serine recombinases, despite their diverse sequences.

To assess whether the contigs identified by RADS (hereafter referred to as RADS contigs) had

known antiphage defense systems we used DefenseFinder to query these DNA sequences[14]. Previously

characterized antiphage defense systems were grouped into one of eight categories: abortive infection,

CBASS, nucleic acid restriction, CRISPR-Cas, toxin/antitoxin, retron, RNA degradation, and unknown

mechanism. Known antiphage defense systems were found in high abundance within these contigs at a

discovery rate of 36.5% (**Fig.2B**). The most abundant antiphage defense category identified among the

Bacillota were restriction enzymes (**Fig. 2B)**, which were found to be distributed across many nucleic

acid restriction categories (**Fig. 2C**). EF_B0058 was originally discovered upstream of a TIV-RE system,

indicating these recombinases are often associated with nucleic acid restriction systems. The second

Figure 2. RADS identifies known antiphage defenses across genera in the Bacillota phylum. (A) Alphafold3 modeling of EF_B0058 and its 9 lowest-homology homologs from the Bacillota dataset (gray) aligned to the *Escherichia* phage Mu serine recombinase (red). RMSD=1.4. (B) Quantification of antiphage system categories, (C) nucleic acid restriction types, or (D) abortive infection types identified by DefenseFinder in Bacillota RADS contigs, respectively. (E) Heatmap of antiphage system categories identified across genera in the Bacillota phylum. Green boxes around genus names indicate taxonomic families, while gray boxes indicate orders.

205   most common category identified was abortive infection systems (**Fig. 2B**), with those identified

206   representing a wide array of systems and mechanisms (**Fig. 2D**). These data show that characterized

207   antiphage defense systems can be identified in RADS contigs.

208   Traditional antiphage defense system search methods has historically limited the diversity of

bacteria interrogated. We sought to demonstrate that RADS could identify known antiphage defense

systems in diverse bacteria. To first illustrate this, we assessed the distribution of known antiphage

defense systems across genera in the Bacillota phylum. Antiphage defense systems were observed in

contigs from fourteen bacterial genera, spanning five families and two orders (**Fig. 2E**). These data show

that RADS can identify antiphage systems in bacteria that have been previously neglected for antiphage

defense discovery.

RADS identifies an abundance of antiphage defense systems from microbiomes

To test the utility of RADS for finding antiphage defense systems in diverse phyla of bacteria from

polymicrobial communities, we ran the pipeline on a large publicly available human fecal microbiome

dataset[32]. We acquired 711 metagenome assemblies from pooled and un-pooled samples

(encompassing a total of 2,441 samples) from the Human Microbiome Project Data Analysis and

Coordination Center (DACC)[32] (accessed July 2024). Using these data, we asked whether serine

recombinases were distributed evenly across phyla. We first determined the bacterial taxonomy using

kraken2 with the phanta database[33], revealing Bacillota (67.14%), Bacteroidota (24.23%),

Pseudomonadota (3.21%), Uroviricota (2.26%), and Actinomycetota (1.75%) to be the most abundant

phyla (**Fig. 3A**). Contigs containing moderate homology to the EF_B0058 serine recombinase (≥30%

amino acid identity) were identified using RADS with a discovery rate of 0.016%. Serine recombinase-

containing contigs shared a similar taxonomic distribution compared to the input dataset, revealing

contigs from Bacillota (69.41%), Bacteroidota (21.34%), Pseudomonadota (3.26%), Uroviricota (3.03%),

and Actinomycetota (2.27%) to be most abundant (**Fig. 3A**). This shows that these serine recombinases

are well distributed across microbial phyla and that RADS can identify them in a manner that is not biased

toward a single phylum.

We next sought to determine if RADS could identify known antiphage defense systems in the

diverse phyla from these metagenomes. Abortive infection, CBASS, CRISPR-Cas, nucleic acid

restriction, retron, toxin/antitoxin, and systems of unknown mechanism were identified across nine phyla

at high abundance with an antiphage discovery rate of 30.2% in RADS contigs (**Fig. 3B**). Notably, the

distribution of phyla in which antiphage systems were identified is similar to the distribution of phyla in

the input and output datasets.

To demonstrate that RADS is broadly applicable to bacteria from different niches, we ran the

pipeline on a previously published soil microbiome dataset encompassing 3,304 metagenomes[31]. RADS

Figure 3. RADS identifies known antiphage defenses across diverse phyla. (A,B) Human fecal microbiome metagenomes or (C,D) soil microbiome metagenomes were run through the RADS pipeline, respectively. (A,C) Distribution of phyla identified by Kraken2 in the input dataset vs the contigs that came out of the RADS pipeline (output). (B,D) Quantification of antiphage system categories identified by DefenseFinder, where fill color represents the distribution of that category across different phyla.

contigs were identified at a discovery rate of 0.003% using moderate homology. While this discovery rate

is approximately five-fold lower than observed for the gut microbiome dataset, this may be explained by

contig quality of the input data. The average contig length for the soil metagenomes was 249.6bp, with a

maximum length of 7,103bp. Meanwhile, the mean average and mean maximum length of the gut

microbiome dataset was 1796bp and 186,996bp, respectively. Importantly, input and output phyletic

distributions were similar in the soil metagenomes with Bacillota being a minority in the output dataset,

further supporting RADS as an unbiased approach (**Fig. 3C**). We identified 34 antiphage defense

systems in these RADS contigs, with a discovery rate of 85% (**Fig. 3D**).

To further substantiate that RADS can identify antiphage defenses in phyla divergent from the

Bacillota, we ran RADS on genomes from the Bacteroidota. We pulled all Bacteroidota entries from NCBI

(accessed July 2024), then randomly selected 33,520 entries, which encompassed metagenomic contigs

and assembled genomes from a variety of genera within the phylum. RADS contigs were identified using

moderate homology at a discovery rate of 9.8%. Not only were an overwhelming abundance of known

antiphage defense systems discovered using RADS on the Bacteroidota (77.4% discovery rate) (**Fig.**

4A), but these systems were distributed across 13 families encompassing 4 orders (**Fig. 4B**). The most

abundant defense system category of the Bacteroidota were toxin/antitoxin systems followed closely by

nucleic acid defense systems similar to that observed for the Bacillota (**Fig. 4C, 4D**).

Altogether, these data validate RADS as a robust method for identifying putative antiphage

defenses across highly diverse bacterial genomes in an unbiased manner.

Figure 4. RADS identifies known antiphage defenses in the Bacteroidota. (A) Quantification of antiphage defense categories identified in the Bacteroidota. (B) Distribution of antiphge defense categories across families in the Bacteroidota. Gray boxes around family names indicate taxonomic orders. (C,D) Quantification of systems identified by Defense Finder that are in the (C) toxin/Antitoxin or (D) nucleic Acid Restriction categories.

With the success of using the EF_B0058 serine recombinase as bait for identifying antiphage

defenses, we questioned whether this may be a general feature of recombinases. To test this, we utilized

a tyrosine recombinase as bait. Similar to the serine recombinases, tyrosine recombinases are widely

distributed in prokaryotic genomes and are involved in transposon mobility and prophage integration[35].

We ran RADS with either the *Bacteroides fragilis* tyrosine recombinase *tsr25*[36] or a *Clostridia* tyrosine-

type recombinase/integrase (NCBI accession MFQ9799422.1). This recombinase was selected from

Clostridia because it was the most closely related tyrosine recombinase to *tsr25* in the Bacillota phylum.

Using these baits, RADS was then run on either the Bacillota phylum or the 33,520 randomly selected

Bacteroidota genomes (**Fig. S1**).

Figure S1. Tyrosine recombinases do not reliably identify antiphage defenses across phyla. Tyrosine recombinases were used as queries in the RADS pipeline on the Bacillota and Bacteroidota phyla. Graphic depicts searches performed with number of hits (recombinase homologs) and antiphage systems discovered noted. Graphs represent the antiphage defense system categories identified in tyrosine recombinase contigs.

Notably, these tyrosine recombinases exhibited phylum bias with very few homologs of both baits

found in the Bacillota and a multitude of homologs of both baits found in the Bacteroidota dataset. When

homologs were identified, an overwhelming abundance of antiphage defenses were noted in their

surrounding 10kb contig, particularly restriction enzymes (**Fig. S1**). Notably, the same antiphage

defenses were identified by both baits in the Bacteroidota phylum. This data highlights that while

recombinases more generally may be found surrounding antiphage defense systems, serine

recombinases exhibit unique phylum-level impartiality.

Binomial and co-transcriptional analyses reveal novel antiphage defense genes using RADS

Knowing that we could bioinformatically identify previously characterized antiphage defense systems

using RADS, we next sought to determine if RADS could be used to identify uncharacterized antiphage

defense systems. We focused our efforts on the dataset generated from the Bacillota phylum (**Fig. 2**). To

prioritize potential antiphage defense systems for further investigation, we employed a binomial statistical

analysis paired with co-transcriptional prediction between the serine recombinase gene and genes

containing one or more assigned pfam domain (identified by InterProScan, **Table S2**). The co-

transcriptional analysis determines if an ORF following a serine recombinase gene is on the same DNA

Figure S2. Additional analyses utilized to select ORFs to test for antiphage activity. (A) Graphic depicting the co-transcriptional analysis. ORFs were required to be on the same strand and within 100bp to determine they are likely to be co-transcribed. (B) Graphic depicting the binomial analysis. The frequency of finding a given domain in RADS contigs versus the genome was compared to the overall distribution of domains in contigs compared to domains in the genome. Comparing these frequencies allowed us to assign a statistical measure to how enriched domains were in contigs.

284   strand and if its predicted start site is within the broad distance of 100bp of the end of the serine

285   recombinase[37,38] (**Fig. S2A**). If both conditions are met, the ORF is flagged as likely to be co-transcribed.

286   The binomial statistical analysis reports the enrichment of a given domain within a RADS contig compared

287   to the entire pangenome of the input dataset (**Fig. S2B**).

Figure 5. Discovery of previously uncharacterized antiphage defenses in RADS contigs. (A) Scatter plot of domains found in RADS contigs where n represents the number of instances in RADS contigs. The higher the value on the y axis, the more statistically enriched the domain. Green points represent domains chosen to test. (B) Heatmap of mean Log10(fold-change efficiency of plaquing (EOP)) of phages (X-axis) on *E. faecalis* OG1RF strains carrying ORF of interest (Y-axis) compared to strains carrying an empty vector. The more negative the EOP value, the better the antiphage defense. ORFs from each contig selected are depicted under the name of each system. Light green arrows indicates the ORF tested. Red arrows indicate recombinases.

Nine ORFs predicted to be co-transcribed with significantly enriched domains by binomial

statistical testing using Benjamini-Hochberg-corrected P-values (**Fig. 5A, Table S3**) were selected for

testing for antiphage defense activity (**Fig. 5B**). Tested ORFs include genes encoding domains of

unknown function (DUF) - DUF5677 and DUF6056, and genes predicted to encode putative Abi, AAA

ATPase, phage head morphogenesis, superinfection exclusion, Schlafen, and KAP (Kidins220/ARMS

and PifA) P-Loop NTPase domains (**Table S1, S3**). We prioritized the selection of ORFs from

Enterococcus or other lactic acid bacteria to maximize the likelihood of successfully expressing these

proteins in our model bacterium *E. faecalis* OG1RF, a strain that lacks prophages and other MGEs[39-41].

ORFs were selected from four *Enterococcus* species; *faecalis, faecium, hirae,* and *avium,* as well as

Lactobacillus helveticus and *Vagococcus fluvialis* (**Table S1**).

We cloned these candidate antiphage defense genes and constitutively expressed them in *E.*

faecalis OG1RF. We tested a panel of six genomically diverse *E. faecalis* phages for their ability to infect

these strains[24,25,42,43]. Plaque forming units (PFU) per mL were measured and compared between *E.*

faecalis cells expressing a potential antiphage defense system and cells carrying the empty vector to

generate a fold change Efficiency of Plaquing (EOP) (**Fig. 5B, S3A**). This experiment revealed that three

of the nine ORFs tested were potent antiphage defenses with EOP being decreased by up to six log-fold

change and included the KAP P-Loop NTPase, Schlafen, and superinfection exclusion domain containing

Figure S3. Raw values of EOP experiments. (A,B,C) Raw triplicate values (points) and means (bars) of EOP experiments in Figure 5B (A), Figure 6B (B), and Figure 6D (C). P-values determined by one-tailed one-sample t test compared against theoretical value of 1 (n=3, a < 0.0001, b < 0.01, c < 0.05).

306 proteins (**Fig. 5B, S3A).** An additional two showed weak to moderate antiphage defense; a AAA ATPase

307 and an undescribed Abi system domain containing proteins (**Fig. 5B, S3A**).

KAP P-loop NTPase domains are fused to antiphage effector domains

310 As KAP P-loop NTPAases have not been robustly explored in association with antiphage defense, we

311 focused our efforts on this system. To further probe the function of the *E. faecalis* KAP NTPase ORF

312 (EF_KAP), we tested this system against various multiplicities of infection (MOIs) of phage. We first

313 determined that EF_KAP does not function through abortive infection as it is equally protective at low (1)

314 and high (10) MOIs **(Fig. S4).** AlphaFold3 modeling of EF_KAP suggests it consists of two N-terminal

Figure S4. EF_KAP does not protect from phage via abortive infection. OD_{600} of cultures was measured over time in the presence or absence of phage infection (phages G01, NPV1, and Phi17) at MOI of 1 or 10. EV indicates host strain (*E. faecalis* OG1RF) carries empty vector, while EF_KAP indicates host strain carries plasmid expressing EF_KAP. Lines represent mean of two biological replicates of technical triplicates.

transmembrane helices, followed by the KAP NTPase domain **(Fig. 6A)**. KAP P-loop NTPases have been

previously reported to regulate diverse proteins across the tree of life[44]. Notably, in prokaryotes these

enzymes are hypothesized to regulate membrane-associated signaling complexes involved in restriction

of foreign DNA[44]. A KAP P-loop NTPase domain is found in PifA, a protein encoded by the enterobacterial

F plasmid that restricts phage T7, however it has been noted that phage restriction is likely not the primary

function of this protein nor is the mechanism of action known[45]. In the case of EF_KAP, the

transmembrane and KAP NTPase regions are followed by a 322 amino acid region with no known

domains or predicted similarity to proteins of known function. This suggests that this KAP-NTPase is

fused to an uncharacterized antiphage effector domain that may be activated by KAP-NTPase activity.

To begin to unravel how EF_KAP mediates protection against phage, we first generated two

amino acid substitutions (D246A, D247A) in the Walker B motif of the KAP NTPase domain, which has

been previously shown to be necessary for catalytic function by nucleotide hydrolysis[44]. Mutation of the

Walker B motif ablated antiphage defense (**Fig. 6B, S3B**). These single amino acid mutations of the

Walker B region suggest that this protein is not preventing phage adsorption, but rather its enzymatic

activity prevents phage replication.

We next sought to test whether KAP NTPase domains may regulate other fused putative effector

domains that have antiphage function and are divergent from EF_KAP. To explore this, we selected three

KAP P-Loop NTPase domain-containing ORFs from the human fecal microbiome metagenomic RADS

contigs with diverse putative effector regions (**Fig. 6C**). These ORFs were selected from diverse host

Figure 6. KAP P-Loop NTPases are associated with antiphage effector regions. (A) Alphafold3 modeling of EF_KAP where teal indicates the transmembrane helices, red indicates the KAP NTPase domain, white indicates the Walker B motif within the KAP NTPase region, and green indicates the effector region. (B) Heatmap of mean Log10(fold-change efficiency of plaquing (EOP)) of phages (Y) on E. faecalis OG1RF strains carrying EF_KAP or EF_KAP with WalkerB Mutation (X). The more negative the EOP value, the better the antiphage defense. (C) Alphafold3 modeling of KAP P-Loop NTPase domain (red) containing proteins with diverse effector regions (green). (D) Heatmap of mean Log10(fold-change efficiency of plaquing (EOP)) of phages (Y) on E. faecalis OG1RF strains carrying each diverse KAP P-Loop NTPase domain protein compared to strain carrying empty vector. The more negative the EOP value, the better the antiphage defense.

bacteria (*Faecalibacterium, Lachnospira*, and an unclassified contig) and predicted structural similarity to

characterized proteins. Importantly, we found that these three ORFs conferred protection from phage

infection in *E. faecalis* (**Fig. 6D, S3C**).

Together, these data indicate that KAP P-Loop NTPases that are fused to putative effector

domains belong to an undescribed class of antiphage defense proteins.

<u>Discussion</u>

In this study we developed a bioinformatic pipeline for identifying antiphage defense systems, which

we have named Recombinase Associated Defense Search (RADS). This pipeline leverages a serine

recombinase as genomic 'bait' to identify adjacently encoded putative antiphage defense systems. RADS

identifies antiphage defense systems in a manner unbiased by bacterial taxonomy. Additionally, we

leveraged the predictive power of RADS to identify previously uncharacterized antiphage defense

systems.

Prior work has utilized bioinformatic strategies to identify antiphage defense systems[5-7]. However,

these studies use known antiphage defense systems, prophages, or DNA genomic libraries to identify

genomic regions that may assemble into defense islands[5-9,46]. Although an effective strategy, this

approach is limited in the context of the genomic regions queried in a reference genome and is skewed

toward specific bacterial species. RADS represents a major step forward in the identification of antiphage

defenses as it begins to more evenly assess these systems across diverse bacterial phyla. RADS

includes a ranking scheme for ORFs likely to be involved in antiphage defense through their statistical

enrichment in contigs and their likelihood of being co-transcribed with a serine recombinase gene based

on genomic proximity. RADS streamlines the identification of candidate antiphage defense systems in a

high throughput manner.

Herein, we test nine ORFs identified using RADS for their ability to protect against phage infection,

discovering three highly potent and two moderate antiphage defense systems. However, this only begins

to scratch the surface of ORFs present in these RADS identified contigs. There are 425 domains that are

enriched in Bacillota contigs that have potential to be antiphage defense systems, regardless of co-

transcription status. Multiple ORFs with diverse sequences can contain identical domains, thus studying

how a given domain functions across diverse ORFs could provide new insights into domain function.

Finally, ORFs identified with minimal antiphage defense activity may simply not be active against the

phages tested, or *E. faecalis* OG1RF is an unsuitable heterologous host.

RADS offers a path toward the continued discovery of new biology related to antiphage defense

systems. For instance, KAP P-loop NTPases were hypothesized to be antiphage defense systems by

Aravind *et al.* over 20 years ago[44]. More recently the protein Tmn, a YobI-like P-loop NTPase (as

determined by InterProScan), with transmembrane helices following the Walker A motif, synergizes with

the Gabija defense system[6,44,47]. Here we show proteins harboring the KAP P-loop NTPase domain are

potent antiphage defenses (**Fig. 5, 6**). We discovered a variety of KAP P-loop NTPases that offer cross-

genus protection against phages (**Fig. 6**). These KAP P-loop NTPases are associated with effector

regions that lack known domains or any structural similarity to characterized proteins. We also show that

the KAP P-Loop NTPases described in our study likely constitute a new class of proteins where the KAP

P-Loop NTPase domain is fused to an antiphage defense effector region.

Expanding on the discovery of previously unrecognized antiphage defense systems, we show

that a Schlafen domain-containing protein from *E. faecium* is a broad and potent antiphage defense

system (**Fig. 5**)*.* Schlafens are mammalian antiviral proteins with extensive activity against eukaryotic

viruses[48] (**Fig. S5A**). However, a recent study also identified Schlafen proteins in prokaryotes that support

antiphage defense, independently corroborating our findings[49]. One such system mediates abortive

infection via host bacterial tRNA cleavage upon recognizing a phage tail assembly protein[49]. This

mechanism is likely conserved with eukaryotic Schlafen protein function where Schlafen domains are

fused to sensor domains that trigger Schlafen antiviral activity[49] (**Fig. S5A**). To date, characterized

prokaryotic Schlafen proteins are fused to sensor domains that impart antiphage function (**Fig. S5A**).

Intriguingly, the Schlafen protein identified in our study exhibits broad antiphage activity via abortive

infection despite its C-terminus lacking any known domains **(Fig. S5A,B).** This suggests that a variety of

yet to be described phage sensing mechanisms are mediated by Schlafen proteins, reminiscent of what

has been observed in eukaryotic organisms[39,48].

Figure S5. Schlafen proteins are conserved antivirals. (A) Comparison between prokaryotic and eukaryotic Schlafen proteins of different groups. Asterisk indicates size of protein is not currently reported. (B) OD_{600} of E. faecalis OG1RF cultures were measured over time in the presence or absence of phage G01 infection at MOI of 0.1, 1, or 10. EV indicates host strain carries empty vector, while Schlafen indicates host strain carries plasmid expressing Schlafen (This study). Lines represent mean of three biological replicates of technical triplicates

Other antiphage defense systems identified in this study had phage-specific and/or moderate to

weak effects on phage infection. This includes a predicted superinfection exclusion protein, a AAA

ATPase, and a putative Abi system of unknown function. Superinfection exclusion proteins support inter-

phage defense, often encoded in prophages, that restrict invading phages[50]. Interestingly, the

superinfection exclusion protein identified in our study is not found within a prophage as determined by

PHASTER[51]. This may represent the hijacking of a superinfection exclusion mechanism without

maintaining the prophage or potential recombination between a phage carrying a superinfection exclusion

mechanism and the host bacterial chromosome. Further study of this superinfection exclusion

mechanism may reveal unrecognized adaptive relationships between infecting phages and their host

bacteria that promotes antiphage defense.

Due to the breadth of antiphage defense genes found associated with serine recombinase genes,

it is likely that this co-occurrence represents more than just evolutionary synteny. Rather, we propose

that this link between serine recombinase genes and antiphage defense systems represents a broader

evolutionary adaptation. One potential hypothesis for this is that antiphage defenses systems are

mobilized by horizontal gene transfer via prophages or plasmids[17-20]. However, maintenance of such

genetic elements can impose fitness constraints, such as the observation that plasmid maintenance can

decrease bacterial growth rate[52]. We postulate that these serine recombinases may help mobilize

antiphage defenses to the chromosome, thereby minimizing the need for carriage of costly mobile genetic

elements and reducing fitness costs. Alternatively, these serine recombinases may serve to diversify the

host genome upon phage predation while working in tandem with the antiphage defense system to block

phage infection. Diverse populations are more resilient to infection[53], and this could be a mechanism

whereby genetic flexibility of phage defense systems through rapid recombination and horizontal gene

transfer supports population resilience.

Acknowledgements

This work was supported by NIH grants R01AI1414791 and R01AI171046 (BAD) and National Science

Foundation Graduate Research Fellowship AWD-230884 (SEA).

<u>**References**</u>

1   Kortright, K. E., Chan, B. K., Koff, J. L. & Turner, P. E. Phage therapy: A renewed approach to

combat antibiotic-resistant bacteria. *Cell Host Microbe* **25**, 219-232 (2019).

doi:10.1016/j.chom.2019.01.014

2   Strathdee, S. A., Hatfull, G. F., Mutalik, V. K. & Schooley, R. T. Phage therapy: From biological

mechanisms to future directions. *Cell* **186**, 17-31 (2023). doi:10.1016/j.cell.2022.11.017

3   Suh, G. A., Lodise, T. P., Tamma, P. D., Knisely, J. M., Alexander, J., Aslam, S., Barton, K. D.,

Bizzell, E., Totten, K. M. C., Campbell, J. L., Chan, B. K., Cunningham, S. A., Goodman, K. E.,

Greenwood-Quaintance, K. E., Harris, A. D., Hesse, S., Maresso, A., Nussenblatt, V., Pride, D.,

Rybak, M. J., Sund, Z., van Duin, D., Van Tyne, D. & Patel, R. Considerations for the use of

phage therapy in clinical practice. *Antimicrob Agents Chemother* **66**, e0207121 (2022).

doi:10.1128/aac.02071-21

4   Bernheim, A. & Sorek, R. The pan-immune system of bacteria: antiviral defence as a community

resource. *Nat Rev Microbiol* **18**, 113-119 (2020). doi:10.1038/s41579-019-0278-2

5   Doron, S., Melamed, S., Ofir, G., Leavitt, A., Lopatina, A., Keren, M., Amitai, G. & Sorek, R.

Systematic discovery of antiphage defense systems in the microbial pangenome. *Science* **359**

(2018). doi:10.1126/science.aar4120

6   Gao, L., Altae-Tran, H., Böhning, F., Makarova, K. S., Segel, M., Schmid-Burgk, J. L., Koob, J.,

Wolf, Y. I., Koonin, E. V. & Zhang, F. Diverse enzymatic activities mediate antiviral immunity in

prokaryotes. *Science* **369**, 1077-1084 (2020). doi:10.1126/science.aba0372

7   Millman, A., Melamed, S., Leavitt, A., Doron, S., Bernheim, A., Hör, J., Garb, J., Bechon, N.,

Brandis, A., Lopatina, A., Ofir, G., Hochhauser, D., Stokar-Avihail, A., Tal, N., Sharir, S., Voichek,

M., Erez, Z., Ferrer, J. L. M., Dar, D., Kacen, A., Amitai, G. & Sorek, R. An expanded arsenal of

immune systems that protect bacteria from phages. *Cell Host Microbe* **30**, 1556-1569.e1555

(2022). doi:10.1016/j.chom.2022.09.017

8   Vassallo, C. N., Doering, C. R., Littlehale, M. L., Teodoro, G. I. C. & Laub, M. T. A functional

selection reveals previously undetected anti-phage defence systems in the *E. coli* pangenome.

Nat Microbiol **7**, 1568-1579 (2022). doi:10.1038/s41564-022-01219-4

9   Rodriguez-Rodriguez, L., Pfister, J., Schuck, L., Martin, A. E., Mercado-Santiago, L. M.,

Tagliabracci, V. S. & Forsberg, K. J. Metagenomic selections reveal diverse antiphage defenses

in human and environmental microbiomes. *Cell Host Microbe* **33**, 1381-1395 e1387 (2025).

doi:10.1016/j.chom.2025.07.005

10   Rousset, F., Depardieu, F., Miele, S., Dowding, J., Laval, A.-L., Lieberman, E., Garry, D., Rocha,

E. P. C., Bernheim, A. & Bikard, D. Phages and their satellites encode hotspots of antiviral

systems. *Cell Host & Microbe* **30**, 740-753.e745 (2022). doi:10.1016/j.chom.2022.02.018

11   Ofir, G., Herbst, E., Baroz, M., Cohen, D., Millman, A., Doron, S., Tal, N., Malheiro, D. B. A.,

Malitsky, S., Amitai, G. & Sorek, R. Antiviral activity of bacterial TIR domains via immune

signalling molecules. *Nature* **600**, 116-120 (2021). doi:10.1038/s41586-021-04098-7

12   Tal, N., Millman, A., Stokar-Avihail, A., Fedorenko, T., Leavitt, A., Melamed, S., Yirmiya, E.,

Avraham, C., Brandis, A., Mehlman, T., Amitai, G. & Sorek, R. Bacteria deplete

deoxynucleotides to defend against bacteriophage infection. *Nat Microbiol* **7**, 1200-1209 (2022).

doi:10.1038/s41564-022-01158-0

13   Whiteley, A. T., Eaglesham, J. B., de Oliveira Mann, C. C., Morehouse, B. R., Lowey, B.,

Nieminen, E. A., Danilchanka, O., King, D. S., Lee, A. S. Y., Mekalanos, J. J. & Kranzusch, P. J.

Bacterial cGAS-like enzymes synthesize diverse nucleotide signals. *Nature* **567**, 194-199

(2019). doi:10.1038/s41586-019-0953-5

14   Tesson, F., Hervé, A., Mordret, E., Touchon, M., d'Humières, C., Cury, J. & Bernheim, A.

Systematic and quantitative view of the antiviral arsenal of prokaryotes. *Nat Commun* **13**, 2561

(2022). doi:10.1038/s41467-022-30269-9

15   Yamaguchi, T., Ono, D. & Sato, A. Staphylococcal cassette chromosome *mec* (SCC*mec*)

analysis of MRSA. *Methods Mol Biol* **2069**, 59-78 (2020). doi:10.1007/978-1-4939-9849-4_4

16   Ross, B. D., Verster, A. J., Radey, M. C., Schmidtke, D. T., Pope, C. E., Hoffman, L. R., Hajjar,

A. M., Peterson, S. B., Borenstein, E. & Mougous, J. D. Human gut bacteria contain acquired

interbacterial defence systems. *Nature* **575**, 224-228 (2019). doi:10.1038/s41586-019-1708-z

17   Beamud, B., Benz, F. & Bikard, D. Going viral: The role of mobile genetic elements in bacterial

immunity. *Cell Host & Microbe* **32**, 804-819 (2024). doi:10.1016/j.chom.2024.05.017

18   Beavogui, A., Lacroix, A., Wiart, N., Poulain, J., Delmont, T. O., Paoli, L., Wincker, P. & Oliveira,

P. H. The defensome of complex bacterial communities. *Nat Commun* **15**, 2146 (2024).

doi:10.1038/s41467-024-46489-0

19   Hochhauser, D., Millman, A. & Sorek, R. The defense island repertoire of the *Escherichia coli*

pan-genome. *PLoS Genet* **19**, e1010694 (2023). doi:10.1371/journal.pgen.1010694

20   Fillol-Salom, A., Rostøl, J. T., Ojiogu, A. D., Chen, J., Douce, G., Humphrey, S. & Penadés, J. R.

Bacteriophages benefit from mobilizing pathogenicity islands encoding immune systems against

competitors. *Cell* **185**, 3248-3262.e3220 (2022). doi:10.1016/j.cell.2022.07.014

21   Hossain, M., Aslan, B. & Hatoum-Aslan, A. Tandem mobilization of anti-phage defenses

alongside SCC*mec* elements in staphylococci. *Nat Commun* **15**, 8820 (2024).

doi:10.1038/s41467-024-53146-z

22   Botelho, J. Defense systems are pervasive across chromosomally integrated mobile genetic

elements and are inversely correlated to virulence and antimicrobial resistance. *Nucleic Acids*

Res **51**, 4385-4397 (2023). doi:10.1093/nar/gkad282

23   Bullen, N. P., Johnson, C. N., Andersen, S. E., Arya, G., Marotta, S. R., Lee, Y. J., Weigele, P.

R., Whitney, J. C. & Duerkop, B. A. An enterococcal phage protein inhibits type IV restriction

enzymes involved in antiphage defense. *Nat Commun* **15**, 6955 (2024). doi:10.1038/s41467-

024-51346-1

24   Chatterjee, A., Johnson, C. N., Luong, P., Hullahalli, K., McBride, S. W., Schubert, A. M.,

Palmer, K. L., Carlson, P. E., Jr. & Duerkop, B. A. Bacteriophage resistance alters antibiotic-

mediated intestinal expansion of enterococci. *Infect Immun* **87** (2019). doi:10.1128/iai.00085-19

25   Duerkop, B. A., Huo, W., Bhardwaj, P., Palmer, K. L. & Hooper, L. V. Molecular basis for lytic

bacteriophage resistance in enterococci. *mBio* **7** (2016). doi:10.1128/mBio.01304-16

26   Hyatt, D., Chen, G.-L., LoCascio, P. F., Land, M. L., Larimer, F. W. & Hauser, L. J. Prodigal:

prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics* **11**,

119 (2010). doi:10.1186/1471-2105-11-119

27   Buchfink, B., Reuter, K. & Drost, H.-G. Sensitive protein alignments at tree-of-life scale using

DIAMOND. *Nat Methods* **18**, 366-368 (2021). doi:10.1038/s41592-021-01101-x

28   Shen, W., Sipos, B. & Zhao, L. SeqKit2: A Swiss army knife for sequence and alignment

processing. *Imeta* **3**, e191 (2024). doi:10.1002/imt2.191

29   Jones, P., Binns, D., Chang, H.-Y., Fraser, M., Li, W., McAnulla, C., McWilliam, H., Maslen, J.,

Mitchell, A., Nuka, G., Pesseat, S., Quinn, A. F., Sangrador-Vegas, A., Scheremetjew, M., Yong,

S.-Y., Lopez, R. & Hunter, S. InterProScan 5: genome-scale protein function classification.

Bioinformatics **30**, 1236-1240 (2014). doi:10.1093/bioinformatics/btu031

30   Abramson, J., Adler, J., Dunger, J., Evans, R., Green, T., Pritzel, A., Ronneberger, O., Willmore,

L., Ballard, A. J., Bambrick, J., Bodenstein, S. W., Evans, D. A., Hung, C.-C., O'Neill, M.,

Reiman, D., Tunyasuvunakool, K., Wu, Z., Žemgulytė, A., Arvaniti, E., Beattie, C., Bertolli, O.,

Bridgland, A., Cherepanov, A., Congreve, M., Cowen-Rivers, A. I., Cowie, A., Figurnov, M.,

Fuchs, F. B., Gladman, H., Jain, R., Khan, Y. A., Low, C. M. R., Perlin, K., Potapenko, A., Savy,

P., Singh, S., Stecula, A., Thillaisundaram, A., Tong, C., Yakneen, S., Zhong, E. D., Zielinski, M.,

Žídek, A., Bapst, V., Kohli, P., Jaderberg, M., Hassabis, D. & Jumper, J. M. Accurate structure

prediction of biomolecular interactions with AlphaFold 3. *Nature* **630**, 493-500 (2024).

doi:10.1038/s41586-024-07487-w

31   Ma, B., Lu, C., Wang, Y., Yu, J., Zhao, K., Xue, R., Ren, H., Lv, X., Pan, R., Zhang, J., Zhu, Y. &

Xu, J. A genomic catalogue of soil microbiomes boosts mining of biodiversity and genetic

resources. *Nat Commun* **14**, 7318 (2023). doi:10.1038/s41467-023-43000-z

32   Gevers, D., Knight, R., Petrosino, J. F., Huang, K., McGuire, A. L., Birren, B. W., Nelson, K. E.,

White, O., Methé, B. A. & Huttenhower, C. The Human Microbiome Project: a community

resource for the healthy human microbiome. *PLoS Biol* **10**, e1001377 (2012).

doi:10.1371/journal.pbio.1001377

33   Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. *Genome*

Biology **20**, 257 (2019). doi:10.1186/s13059-019-1891-0

34   Plasterk, R. H., Brinkman, A. & van de Putte, P. DNA inversions in the chromosome of

Escherichia coli and in bacteriophage Mu: relationship to other site-specific recombination

systems. *Proc Natl Acad Sci U S A* **80**, 5355-5358 (1983). doi:10.1073/pnas.80.17.5355

35   Jayaram, M., Ma, C. H., Kachroo, A. H., Rowley, P. A., Guga, P., Fan, H. F. & Voziyanov, Y. An

overview of tyrosine site-specific recombination: From an Flp perspective. *Microbiol Spectr* **3**

(2015). doi:10.1128/microbiolspec.MDNA3-0021-2014

36   Cerdeno-Tarraga, A. M., Patrick, S., Crossman, L. C., Blakely, G., Abratt, V., Lennard, N.,

Poxton, I., Duerden, B., Harris, B., Quail, M. A., Barron, A., Clark, L., Corton, C., Doggett, J.,

Holden, M. T., Larke, N., Line, A., Lord, A., Norbertczak, H., Ormond, D., Price, C.,

Rabbinowitsch, E., Woodward, J., Barrell, B. & Parkhill, J. Extensive DNA inversions in the *B.*

fragilis genome control variable gene expression. *Science* **307**, 1463-1465 (2005).

doi:10.1126/science.1107008

37   Wang, L., Trawick, J. D., Yamamoto, R. & Zamudio, C. Genome-wide operon prediction in

Staphylococcus aureus. *Nucleic Acids Res* **32**, 3689-3702 (2004). doi:10.1093/nar/gkh694

38   Charaniya, S., Mehra, S., Lian, W., Jayapal, K. P., Karypis, G. & Hu, W. S. Transcriptome

dynamics-based operon prediction and verification in *Streptomyces coelicolor*. *Nucleic Acids*

Res **35**, 7222-7236 (2007). doi:10.1093/nar/gkm501

39   Chen, J. & Kuhn, L. A. Deciphering the three-domain architecture in schlafens and the

structures and roles of human *schlafen12* and *serpinB12* in transcriptional regulation. *J Mol*

Graph Model **90**, 59-76 (2019). doi:10.1016/j.jmgm.2019.04.003

40   Palmer, K. L., Godfrey, P., Griggs, A., Kos, V. N., Zucker, J., Desjardins, C., Cerqueira, G.,

Gevers, D., Walker, S., Wortman, J., Feldgarden, M., Haas, B., Birren, B. & Gilmore, M. S.

Comparative genomics of enterococci: variation in *Enterococcus faecalis*, clade structure in *E.*

faecium, and defining characteristics of *E. gallinarum* and *E. casseliflavus*. *mBio* **3**, e00318-

00311 (2012). doi:10.1128/mBio.00318-11

41   Bourgogne, A., Garsin, D. A., Qin, X., Singh, K. V., Sillanpaa, J., Yerrapragada, S., Ding, Y.,

Dugan-Rocha, S., Buhay, C., Shen, H., Chen, G., Williams, G., Muzny, D., Maadani, A., Fox, K.

A., Gioia, J., Chen, L., Shang, Y., Arias, C. A., Nallapareddy, S. R., Zhao, M., Prakash, V. P.,

Chowdhury, S., Jiang, H., Gibbs, R. A., Murray, B. E., Highlander, S. K. & Weinstock, G. M.

Large scale variation in *Enterococcus faecalis* illustrated by the genome analysis of strain

OG1RF. *Genome Biol* **9**, R110 (2008). doi:10.1186/gb-2008-9-7-r110

42   Sheriff, E. K., Andersen, S. E., Chatterjee, A. & Duerkop, B. A. Complete genome sequence of

enterococcal phage G01. *Microbiol Resour Announc* **13**, e0121723 (2024).

doi:10.1128/mra.01217-23

43   Trotter, K. M. & Dunny, G. M. Mutants of *Enterococcus faecalis* deficient as recipients in mating

with donors carrying pheromone-inducible plasmids. *Plasmid* **24**, 57-67 (1990).

doi:10.1016/0147-619X(90)90025-8

44   Aravind, L., Iyer, L. M., Leipe, D. D. & Koonin, E. V. A novel family of P-loop NTPases with an

unusual phyletic distribution and transmembrane segments inserted within the NTPase domain.

Genome Biol **5**, R30 (2004). doi:10.1186/gb-2004-5-5-r30

45   Schmitt, C. K., Kemp, P. & Molineux, I. J. Genes 1.2 and 10 of bacteriophages T3 and T7

determine the permeability lesions observed in infected cells of *Escherichia coli* expressing the

F plasmid gene *pifA*. *J Bacteriol* **173**, 6507-6514 (1991). doi:10.1128/jb.173.20.6507-6514.1991

46   Egorov, A. A., Hauryliuk, V. & Atkinson, G. C. Systematic annotation of hyper-variability hotspots

in phage genomes and plasmids. *bioRxiv*, 2024.2010.2015.618418 (2024).

doi:10.1101/2024.10.15.618418

47 Wu, Y., Garushyants, S. K., van den Hurk, A., Aparicio-Maldonado, C., Kushwaha, S. K., King,

C. M., Ou, Y., Todeschini, T. C., Clokie, M. R. J., Millard, A. D., Gencay, Y. E., Koonin, E. V. &

Nobrega, F. L. Bacterial defense systems exhibit synergistic anti-phage activity. *Cell Host*

Microbe **32**, 557-572 e556 (2024). doi:10.1016/j.chom.2024.01.015

48 Jo, U. & Pommier, Y. Structural, molecular, and functional insights into Schlafen proteins. *Exp*

Mol Med **54**, 730-738 (2022). doi:10.1038/s12276-022-00794-0

49 Taboada, V. P., Wu, Y., Cassidy, R., Medvedev, K. E., Loeff, L., Nemudraia, A. & Nemudryi, A.

Bacterial Schlafens mediate anti-phage defense. *bioRxiv*, 2025.2007.2024.666596 (2025).

doi:10.1101/2025.07.24.666596

50 Bucher, M. J. & Czyż, D. M. Phage against the machine: The SIE-ence of superinfection

exclusion. *Viruses* **16** (2024). doi:10.3390/v16091348

51 Arndt, D., Grant, J. R., Marcu, A., Sajed, T., Pon, A., Liang, Y. & Wishart, D. S. PHASTER: a

better, faster version of the PHAST phage search tool. *Nucleic Acids Res* **44**, W16-21 (2016).

doi:10.1093/nar/gkw387

52 Baltrus, D. A. Exploring the costs of horizontal gene transfer. *Trends Ecol Evol* **28**, 489-495

(2013). doi:10.1016/j.tree.2013.04.002

53 Gibson, A. K. Genetic diversity and disease: The past, present, and future of an old idea.

Evolution **76**, 20-36 (2022). doi:10.1111/evo.14395